Headache & Pain

Filter Your Results

 

News

 

Personal Pain Management App Approved for Use with Intrathecal Drug Delivery Pump

Wednesday, October 24, 2018—The US Food and Drug Administration (FDA) has approved use of an application (myPTM Personal Therapy Manager; Medtronic, Dublin, Ireland) for patients with chronic pain to use…

First Patient Treated in Trial of BHV-3500—A Nasally Delivered CGRP-Receptor Antagonist Being Investigated for Migraine

Tuesday, October 23, 2018—The first participant has been treated in a clinical trial of BHV-3500 (Biohaven, New Haven, CT) for the treatment of patients with migraine. The first intranasal formulation …

Medtronic Launches Control Workflow—An Evidence-Based Protocol for Use With Intrathecal Drug Delivery Pump for Effective Pain Relief

Friday, October 19, 2018—The Control Workflow system (Medtronic, Dublin, Ireland) is an evidence-based approach for use with the intrathecal drug delivery pump (SynchroMed II; Medtronic) to assist phy…

Safety Confirmed for Ubrogepant—A Small-Molecule Oral CGRP Receptor Antagonist for Treatment of Acute Migraine

Wednesday, October 17, 2018—Safety and tolerability studies have been completed for ubrogepant (Allergan, Dublin, Ireland) in patients with acute migraine over 1 year (NCT2867709) and in healthy voluntee…

FDA Approves Galcanezumab for Prevention of Migraine

Friday, September 28, 2018—The Food and Drug Administration (FDA) has approved galcanezumab-glnm (Emgality; Lilly, Indianapolis, IN) for the prevention of migraine in adults. Galcanezumab is available a…

Hometown Highlights: Introducing Hometown Highlights

Stephen M. Gollomp, MD

October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.

Headache Horizons: Tuning in to Psychedelics for Treatment of Suicide Headaches

Peter McAllister, MD

October 2018—Neurologists need to understand the phenomenon of using psychedelic drugs for cluster-busting and advocate for appropriate research.

Fremanezumab-vfrm Approved for Prevention of Migraine

Monday, September 17, 2018—The Food and Drug Administration (FDA) has approved fremanezumab-vfrm (Ajovy; Teva Pharmaceutical Industries, Jerusalem, Israel) for prevention of migraine in adults. Fre…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC